Want to see AU:VLS full AI Analyst Report?
VLS Stock Chart & Stats
AU$2.52
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$2.52
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$2.15 - AU$2.84
Previous CloseN/A
Volume18.65K
Average Volume (3M)14.76K
Market Cap
AU$134.30M
Enterprise ValueAU$98.07M
Total Cash (Recent Filing)AU$35.56M
Total Debt (Recent Filing)AU$2.39M
Price to Earnings (P/E)13.4
Beta-0.03
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.33%
Share Statistics
EPS (TTM)0.19
Shares Outstanding54,371,357
10 Day Avg. Volume12,408
30 Day Avg. Volume14,758
Financial Highlights & Ratios
PEG Ratio0.72
Price to Book (P/B)2.57
Price to Sales (P/S)1.55
P/FCF Ratio9.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue expansion over multiple years shows durable end-market demand and successful distribution execution. A doubling of sales since 2020 indicates scalable product-market fit and provides a base for continued investment in channels and R&D, supporting medium-term growth prospects.
High Gross MarginsConsistently high gross margins indicate persistent product-level pricing power and favorable cost structure in core supplements. This margin profile supports durable operating profit generation, enabling reinvestment and dividend capacity even if SG&A rises moderately as the company scales.
Conservative Balance SheetLow leverage and a meaningful equity build provide financial flexibility for organic growth, M&A, or cyclical shocks. Strong recent ROE shows effective capital deployment historically, reducing solvency risk and supporting sustainable shareholder distributions and strategic investments over the coming months.
Bears Say
Margin CompressionA multi-year decline in net margin suggests rising cost pressures or less favourable mix as the business scales. If structural, persistent margin erosion would reduce free cash flow and limit reinvestment or payout capacity unless offset by pricing, efficiency gains, or higher-margin product development.
Cash Flow VolatilityInconsistent cash conversion points to working-capital swings or timing differences that make free cash flow less predictable. This variability can complicate capital allocation, dividend planning and stress testing for expansion, increasing operational risk despite healthy headline profitability.
Declining Returns On CapitalA downward trend in returns suggests incremental investments are yielding lower returns than earlier cycles. Over time this can constrain value creation, requiring either higher growth, improved margins, or more disciplined capital allocation to sustain shareholder returns at prior levels.
Vita Life Sciences Limited News
VLS FAQ
What was Vita Life Sciences Limited’s price range in the past 12 months?
Vita Life Sciences Limited lowest share price was AU$2.15 and its highest was AU$2.84 in the past 12 months.
What is Vita Life Sciences Limited’s market cap?
Vita Life Sciences Limited’s market cap is AU$134.30M.
When is Vita Life Sciences Limited’s upcoming earnings report date?
Vita Life Sciences Limited’s upcoming earnings report date is Aug 20, 2026 which is in 46 days.
How were Vita Life Sciences Limited’s earnings last quarter?
Vita Life Sciences Limited released its earnings results on Feb 16, 2026. The company reported AU$0.1 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.1.
Is Vita Life Sciences Limited overvalued?
According to Wall Street analysts Vita Life Sciences Limited’s price is currently Overvalued.
Does Vita Life Sciences Limited pay dividends?
Vita Life Sciences Limited pays a Semiannually dividend of AU$0.095 which represents an annual dividend yield of 4.33%. See more information on Vita Life Sciences Limited dividends here
What is Vita Life Sciences Limited’s EPS estimate?
Vita Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vita Life Sciences Limited have?
Vita Life Sciences Limited has 54,371,357 shares outstanding.
What happened to Vita Life Sciences Limited’s price movement after its last earnings report?
Vita Life Sciences Limited reported an EPS of AU$0.1 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.958%.
Which hedge fund is a major shareholder of Vita Life Sciences Limited?
Currently, no hedge funds are holding shares in AU:VLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vita Life Sciences Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:VLS Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth AU$915.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.60%
12-Months-Change
Fundamentals
Return on Equity
19.15%
Trailing 12-Months
Asset Growth
14.56%
Trailing 12-Months
Company Description
Vita Life Sciences Limited
Vita Life Sciences Limited is an Australian healthcare company specializing in the formulation, packaging, distribution, and sale of vitamins and nutritional supplements. The company's reach spans Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China. In addition to core supplements, their product range encompasses minerals, various herbs, and superfoods. They offer solutions targeting a broad spectrum of therapeutic areas, including nervous system support, general nutrition, immunity, hair, skin, and nails, liver and digestion, weight management, cardiovascular health, pain and inflammation, pregnancy and breastfeeding, and health specifically for men, women, and children. Products also provide antioxidant benefits and support for bones and joints. Marketed under their prominent brands—Herbs of Gold, VitaHealth, and VitaScience—these offerings are sold through pharmacies and health food channels. Established in 1947, Vita Life Sciences Limited is headquartered in Kirrawee, Australia.
Technical Analysis
Elixinol Wellness
―
Cann Group
―
Epsilon Healthcare Limited
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―
Options Prices
Currently, No data available
---